AR

Ardelyx

- NASDAQ:ARDX
Last Updated 2024-04-26

LinkedIn Profile

Access Ardelyx historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:ardx 235758 Apr 21st, 2024 12:00AM Ardelyx, Inc. 12K 299.00 Open Apr 20th, 2024 10:56PM Apr 20th, 2024 10:56PM Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as early-stage pipeline candidates. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. Open Open 400 Fifth Avenue Waltham MA US 02451 Ardelyx Health Care Pharmaceuticals & Biotechnology
nasdaq:ardx 235758 Apr 20th, 2024 12:00AM Ardelyx, Inc. 12K 299.00 Open Apr 19th, 2024 10:50PM Apr 20th, 2024 04:34PM Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as early-stage pipeline candidates. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. Open Open 400 Fifth Avenue Waltham MA US 02451 Ardelyx Health Care Pharmaceuticals & Biotechnology
nasdaq:ardx 235758 Apr 19th, 2024 12:00AM Ardelyx, Inc. 12K 299.00 Open Apr 18th, 2024 10:56PM Apr 18th, 2024 10:56PM Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as early-stage pipeline candidates. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. Open Open 400 Fifth Avenue Waltham MA US 02451 Ardelyx Health Care Pharmaceuticals & Biotechnology
nasdaq:ardx 235758 Apr 18th, 2024 12:00AM Ardelyx, Inc. 12K 299.00 Open Apr 17th, 2024 10:58PM Apr 18th, 2024 05:54PM Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as early-stage pipeline candidates. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. Open Open 400 Fifth Avenue Waltham MA US 02451 Ardelyx Health Care Pharmaceuticals & Biotechnology
nasdaq:ardx 235758 Apr 17th, 2024 12:00AM Ardelyx, Inc. 12K 299.00 Open Apr 16th, 2024 10:40PM Apr 17th, 2024 02:18PM Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as early-stage pipeline candidates. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. Open Open 400 Fifth Avenue Waltham MA US 02451 Ardelyx Health Care Pharmaceuticals & Biotechnology
nasdaq:ardx 235758 Apr 16th, 2024 12:00AM Ardelyx, Inc. 12K 299.00 Open Apr 15th, 2024 10:41PM Apr 16th, 2024 10:34AM Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as early-stage pipeline candidates. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. Open Open 400 Fifth Avenue Waltham MA US 02451 Ardelyx Health Care Pharmaceuticals & Biotechnology
nasdaq:ardx 235758 Apr 15th, 2024 12:00AM Ardelyx, Inc. 12K 299.00 Open Apr 14th, 2024 10:42PM Apr 15th, 2024 04:15PM Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as early-stage pipeline candidates. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. Open Open 400 Fifth Avenue Waltham MA US 02451 Ardelyx Health Care Pharmaceuticals & Biotechnology
nasdaq:ardx 235758 Apr 14th, 2024 12:00AM Ardelyx, Inc. 12K 296.00 Open Apr 13th, 2024 10:36PM Apr 14th, 2024 10:35AM Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as early-stage pipeline candidates. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. Open Open 400 Fifth Avenue Waltham MA US 02451 Ardelyx Health Care Pharmaceuticals & Biotechnology
nasdaq:ardx 235758 Apr 13th, 2024 12:00AM Ardelyx, Inc. 12K 296.00 Open Apr 12th, 2024 10:26PM Apr 13th, 2024 11:02AM Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as early-stage pipeline candidates. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. Open Open 400 Fifth Avenue Waltham MA US 02451 Ardelyx Health Care Pharmaceuticals & Biotechnology
nasdaq:ardx 235758 Apr 12th, 2024 12:00AM Ardelyx, Inc. 12K 296.00 Open Apr 11th, 2024 10:30PM Apr 12th, 2024 07:57AM Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as early-stage pipeline candidates. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. Open Open 400 Fifth Avenue Waltham MA US 02451 Ardelyx Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.